R&D Trends

Sanofi, Regeneron collaborate on immuno-oncology

Wednesday, July 29, 2015 11:47 AM

Sanofi and Regeneron Pharmaceuticals have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. The two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in phase I testing, and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.

More... »


Deerfield launches $550M healthcare venture-capital fund

Wednesday, July 29, 2015 11:41 AM

Deerfield Management has launched the Deerfield Healthcare Innovations Fund, which will invest in groundbreaking advancements in science that may lead to therapeutic interventions in genetic diseases, cancer and orphan diseases. The venture capital fund also will back new technologies that can transform how therapeutics are developed and improve the way healthcare is delivered to patients.

More... »


Biogen, Parkinson’s Institute and Clinical Center partner

Monday, July 27, 2015 12:28 PM

Biogen and the Parkinson’s Institute and Clinical Center, based in Sunnyvale, Calif., have formed a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate R&D of new PD treatments. The agreement will combine the clinical experience and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development.

More... »

Emergent BioSolutions awarded $19.7M BARDA Ebola contract

Wednesday, July 22, 2015 01:49 PM

Emergent BioSolutions, a global specialty biopharmaceutical company based in Gaithersburg, Md., has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2000 liter scale.

More... »

NIH joins public-private partnership to fund research on autism biomarkers

Wednesday, July 22, 2015 01:43 PM

The NIH, the Foundation for the NIH (FNIH), the Simons Foundation Autism Research Initiative (SFARI) and others will fund a multiyear project to develop and improve clinical research tools for studying autism spectrum disorder (ASD).

More... »

Aslan Pharmaceuticals, National Cancer Center Singapore collaborate

Wednesday, July 22, 2015 01:39 PM

Aslan Pharmaceuticals, an oncology focused biotechnology company, and National Cancer Center Singapore (NCCS) have signed a Memorandum of Understanding (MOU) that will further enhance the study of novel therapeutic agents for the treatment of gastric cancer, hepatocellular carcinoma (liver) and cholangiocarcinoma (bile duct), three common forms of gastrointestinal (GI) cancers that are particularly prevalent in Asia. 

More... »

University of Texas System, Sanofi partner on Sanofi iAwards program

Wednesday, July 15, 2015 12:55 PM

Sanofi recently signed an agreement with The University of Texas System to fund selected research programs focused on the early stages of drug discovery.

More... »

Report: Vaccine products in development have tripled over last decade

Wednesday, July 15, 2015 11:50 AM

Vaccine products in the R&D pipeline have more than tripled since 2005 and annual worldwide sales are on track to reach $40 billion by 2020, according to a recently completed study by the Tufts Center for the Study of Drug Development (CSDD).

More... »

MRC, GSK, five U.K. universities collaborate on difficult disease areas

Wednesday, July 15, 2015 09:11 AM

Medical Research Council (MRC), GlaxoSmithKline and five U.K. universities are collaborating on difficult disease areas. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.

More... »

Report: Personalized medicine is gaining traction but faces challenges

Wednesday, July 15, 2015 09:00 AM

While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, according to a recently completed study by the Tufts Center for the Study of Drug Development (CSDD).

More... »

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs